This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
rsi: Archive
After Plunging 13.0% in 4 Weeks, Here's Why the Trend Might Reverse for Bentley Systems (BSY)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Bentley Systems (BSY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
BSYPositive Net Change
rsi stock-price-movement
AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for AngioDynamics (ANGO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ANGONegative Net Change
rsi stock-price-movement
After Plunging 15.2% in 4 Weeks, Here's Why the Trend Might Reverse for InspireMD (NSPR)
by Zacks Equity Research
InspireMD (NSPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
NSPRPositive Net Change
rsi stock-price-movement
Inovio (INO) Loses 32.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Inovio (INO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
INONegative Net Change
rsi stock-price-movement
Keurig Dr Pepper (KDP) Loses 11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Keurig Dr Pepper (KDP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
KDPNegative Net Change
rsi stock-price-movement
After Plunging 34% in 4 Weeks, Here's Why the Trend Might Reverse for Progress Software (PRGS)
by Zacks Equity Research
Progress Software (PRGS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
PRGSPositive Net Change
rsi stock-price-movement
Shoe Carnival (SCVL) Loses 22.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Shoe Carnival (SCVL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
rsi stock-price-movement
Down 20.3% in 4 Weeks, Here's Why Red Violet (RDVT) Looks Ripe for a Turnaround
by Zacks Equity Research
Red Violet (RDVT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
RDVTPositive Net Change
rsi stock-price-movement
Down 17.4% in 4 Weeks, Here's Why The Cooper Companies (COO) Looks Ripe for a Turnaround
by Zacks Equity Research
The Cooper Companies (COO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
COONegative Net Change
rsi stock-price-movement
Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ABOSNegative Net Change
rsi stock-price-movement